{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chan A"],"funding":["NIAID NIH HHS"],"pagination":["510-519"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7837440"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(6)"],"pubmed_abstract":["<h4>Background</h4>Delayed-release dimethyl fumarate (DMF) has demonstrated robust efficacy in treating patients with relapsing-remitting multiple sclerosis. Decreases in absolute lymphocyte count (ALC) are a well-known pharmacodynamic effect of DMF treatment, but lymphocyte recovery dynamics are not well characterized after discontinuation of DMF.<h4>Methods</h4>Data sources included the Biogen DMF integrated clinical trial data set, a retrospective US chart abstraction study, and data from MSBase. We assessed rate and time course of lymphocyte reconstitution after DMF discontinuation.<h4>Results</h4>The majority of patients who developed lymphopenia while treated with DMF and subsequently discontinued treatment experienced ALC reconstitution. The median time to reach ALC ≥0.8 × 10<sup>9<"],"journal":["Neurology. Clinical practice"],"pubmed_title":["Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS."],"pmcid":["PMC7837440"],"funding_grant_id":["UM1 AI144288"],"pubmed_authors":["Gold R","Wright K","Rose J","Kalincik T","Chan A","Spelman T","Ferraro D","Alvarez E","Bar-Or A","Chen C","Fam S","Wu F","Fox RJ","Butzkueven H","Sola P","McGuigan C","Lechner-Scott J","Haartsen J","Miller C","Gudesblatt M","Hodgkinson S","Spach K"],"additional_accession":[]},"is_claimable":false,"name":"Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.","description":"<h4>Background</h4>Delayed-release dimethyl fumarate (DMF) has demonstrated robust efficacy in treating patients with relapsing-remitting multiple sclerosis. Decreases in absolute lymphocyte count (ALC) are a well-known pharmacodynamic effect of DMF treatment, but lymphocyte recovery dynamics are not well characterized after discontinuation of DMF.<h4>Methods</h4>Data sources included the Biogen DMF integrated clinical trial data set, a retrospective US chart abstraction study, and data from MSBase. We assessed rate and time course of lymphocyte reconstitution after DMF discontinuation.<h4>Results</h4>The majority of patients who developed lymphopenia while treated with DMF and subsequently discontinued treatment experienced ALC reconstitution. The median time to reach ALC ≥0.8 × 10<sup>9<","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2025-04-04T13:04:45.083Z","creation":"2021-02-21T05:04:51Z"},"accession":"S-EPMC7837440","cross_references":{"pubmed":["33510947"],"doi":["10.1212/CPJ.0000000000000800"]}}